New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
16:07 EDTIPXL, ACTImpax acquires two generic products from Actavis
Impax (IPXL) has acquired from Actavis (ACT) two generic products for cash consideration. Financial terms of the agreement were not disclosed. The acquisition includes one product marketed under an Abbreviated New Drug Application - Ursodiol tablet - and one approved ANDA that is not yet marketed - Lamotrigine orally disintegrating tablet.
News For IPXL;ACT From The Last 14 Days
Check below for free stories on IPXL;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
July 16, 2014
11:35 EDTIPXLLannett announces inquiry received from Connecticut Attorney General
Subscribe for More Information
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
09:11 EDTIPXLLannett risk has increased on competitor probe, says Roth Capital
Subscribe for More Information
July 15, 2014
17:10 EDTIPXLImpax receives subpoena related to digoxin sales
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use